Ampyra Trial Failure Is Not All Bad News For Acorda
This article was originally published in The Pink Sheet Daily
Executive Summary
Lower dose of Acorda’s MS drug Ampyra fails to meet primary endpoint in new study, reassuring investors on the IP front. But the higher, approved dose also missed the mark, which raises questions about a negative commercial impact.
You may also be interested in...
“The Pink Sheet” DAILY’s Most Popular Stories Last Week
Obesity and diabetes drug development and market issues drew the most attention from readers.
Ampyra Seizure Warnings Strengthened Followed Continued Reports
The seizure risk for Acorda’s multiple sclerosis drug was already known, but an FDA MedWatch Alert based on post-market adverse event reports says, “the majority of seizures happened within days to weeks after starting the recommended dose and occurred in patients having no history of seizures.”
The Long Road To Approval: Acorda Experience With Ampyra Shows Success Of Novel Analysis Plan
Acorda Therapeutics' challenges in seeking approval for its oral therapy Ampyra to improve walking ability in patients with multiple sclerosis were greater than most from the start: it was a novel drug for a first-of-its-kind claim – and the drug yielded variable efficacy on an unproven endpoint. What seems to have made the difference is the creative analysis plan that Acorda came up with.